Analyst Reco. Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Real-time Estimate Cboe BZX Other stock markets 09:54:46 29/04/2024 pm IST			5-day change	1st Jan Change
6.41 ^USD	+4.06%		-7.95%	-54.37%

03/04	Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating	MT
02/04	Sector Update: Health Care Stocks Slide Late Afternoon	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating	03/04	MT
Rate Outlooks Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday	29/11	MT
Guggenheim Adjusts Price Target on Verve Therapeutics to $55 From $56, Maintains Buy Rating	15/23/15	MT
Canaccord Genuity Starts Verve Therapeutics at Buy With $29 Price Target	13/23/13	MT
Credit Suisse Lowers Verve Therapeutics' Price Target to $32 From $37, Maintains Neutral Rating	03/23/03	MT
Cantor Fitzgerald Initiates Verve Therapeutics at Neutral With $21 Price Target	01/23/01	MT
Goldman Sachs Initiates Verve Therapeutics at Sell With $13 Price Target	15/22/15	MT
RBC Cuts Price Target on Verve Therapeutics to $35 From $42, Maintains Outperform, Speculative Risk Rating	08/22/08	MT
Credit Suisse Starts Verve Therapeutics at Neutral with $48 Price Target	06/22/06	MT
Stifel Raises Verve Therapeutics to Buy From Hold, Price Target to $56 From $32	25/22/25	MT
Guggenheim Adjusts Price Target for Verve Therapeutics to $56 From $64, Maintains Buy Rating	26/22/26	MT
BMO Capital Raises Verve Therapeutics' Price Target to $62 From $48, Maintains Outperform Rating, Shares Climb 21%	18/22/18	MT
Verve Therapeutics Shares Rise After BMO Capital Initiates Coverage at Outperform	17/22/17	MT
BMO Capital Initiates Verve Therapeutics at Outperform With $48 Price Target	17/22/17	MT
Guggenheim Cuts Verve Therapeutics Price Target to $64 From $84, Maintains Buy Rating	21/22/21	MT
Stifel Adjusts Verve Therapeutics' Price Target to $34 From $58, Reiterates Hold Rating	15/22/15	MT
RBC Initiates Verve Therapeutics at Outperform-Speculative Risk, Sees 'A Great Entry Point,' Sets Price Target at $42	18/22/18	MT
VERVE THERAPEUTICS : Stifel Starts Verve Therapeutics at Hold With $58 Price Target	24/21/24	MT
VERVE THERAPEUTICS : William Blair Starts Verve Therapeutics at Outperform	12/21/12	MT
VERVE THERAPEUTICS : Guggenheim Initiates Coverage on Verve Therapeutics With Buy Rating, $84 Price Target	12/21/12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Analyst Reco.

Filters